Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases

References

• Kamminga LM, Bystrykh LV, de Boer A, et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006;107:2170–2179.
   PubMed Web of Science ®Google Scholar
• Bryant RJ, Cross NA, Eaton CL, et al. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007;67:547–556.
   PubMed Web of Science ®Google Scholar
• Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268–273.
   PubMed Web of Science ®Google Scholar
• Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001;112:950–958.
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722–726.
   PubMed Web of Science ®Google Scholar
• Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8:890–896.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 2012;22:506–523.
   PubMed Web of Science ®Google Scholar
• Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA2012; 109:21360–21365.
   PubMed Web of Science ®Google Scholar
• Yan J, Ng SB, Tay JL, et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood 2013;121:4512–4520.
   PubMed Web of Science ®Google Scholar
• Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 2011;223:496–510.
   PubMed Web of Science ®Google Scholar
• Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012;18:298–301.
   PubMed Web of Science ®Google Scholar
• Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012;26:651–656.
   PubMed Web of Science ®Google Scholar
• Zhao X, Lwin T, Zhang X, et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013;27:2341–2350.
   PubMed Web of Science ®Google Scholar
• Sander S, Bullinger L, Klapproth K, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112:4202–4212.
   PubMed Web of Science ®Google Scholar
• Koh CM, Iwata T, Zheng Q, et al. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011;2:669–683.
   PubMed Web of Science ®Google Scholar
• Rojanasakul Y. Linking JNK-STAT3-Akt signaling axis to EZH2 phosphorylation: a novel pathway of carcinogenesis. Cell Cycle 2013;12:202–203.
   PubMed Web of Science ®Google Scholar
• Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005;310:306–310.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Dorfman DM, Greisman HA, Shahsafaei A. Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. Am J Pathol 2003;162: 1539–1544.
   PubMed Web of Science ®Google Scholar
• Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PloS One 2012;7:e33813.
   PubMed Web of Science ®Google Scholar
• Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323–5335.
   PubMed Web of Science ®Google Scholar
• Heightman TD. Therapeutic prospects for epigenetic modulation. Expert Opin Ther Targets 2011;15:729–740.
   PubMed Web of Science ®Google Scholar
• Schneider J, Shilatifard A. Histone demethylation by hydroxylation: chemistry in action. ACS Chem Biol 2006;1:75–81.
   PubMed Web of Science ®Google Scholar
• Chen QW, Zhu XY, Li YY, et al. Epigenetic regulation and cancer (review). Oncol Rep 2014;31:523–532.
   PubMed Web of Science ®Google Scholar
• Mummaneni P, Shord SS. Epigenetics and oncology. Pharmacotherapy 2014;34:495–505.
   PubMed Web of Science ®Google Scholar
• Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121:2253–2263.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28: 3360–3365.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Jeon YK, Paik JH, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology 2008;53:205–217.
   PubMed Web of Science ®Google Scholar
• Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta 2014;1845:136–154.
   PubMed Web of Science ®Google Scholar
• Ding BB, Yu JJ, Yu RY, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008;111:1515–1523.
   PubMed Web of Science ®Google Scholar
• Khoury JD, Medeiros LJ, Rassidakis GZ, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 2003;9:3692–3699.
   PubMed Web of Science ®Google Scholar
• Sonnen R, Schmidt WP, Muller-Hermelink HK, et al. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005;129: 366–372.
   PubMed Web of Science ®Google Scholar
• Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457–463.
   PubMed Web of Science ®Google Scholar
• Wee S, Dhanak D, Li H, et al. Targeting epigenetic regulators for cancer therapy. Ann NY Acad Sci 2014;1309:30–36.
   PubMed Web of Science ®Google Scholar
• Garapaty-Rao S, Nasveschuk C, Gagnon A, et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol 2013; 20:1329–1339.
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108–112.
   PubMed Web of Science ®Google Scholar